Literature DB >> 18930564

New roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer's disease?

Christian Hölscher1, Lin Li.   

Abstract

Type 2 diabetes has been identified as a risk factor for Alzheimer's disease (AD). This is most likely due to the desensitisation of insulin receptors in the brain. Insulin acts as a growth factor and supports neuronal repair, dendritic sprouting, and differentiation. This review discusses the potential role that insulin-like hormones could play in ameliorating the reduced growth factor signalling in the brains of people with AD. The incretins glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) have very similar properties in protecting neurons from toxic effects, and are capable of reversing the detrimental effects that beta-amyloid fragments have on synaptic plasticity. Therefore, incretins show great promise as a novel treatment for reducing degenerative processes in AD. Copyright 2008 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18930564     DOI: 10.1016/j.neurobiolaging.2008.08.023

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  24 in total

Review 1.  Extra-pancreatic effects of incretin-based therapies.

Authors:  Baptist Gallwitz
Journal:  Endocrine       Date:  2014-03-07       Impact factor: 3.633

2.  Early intranasal insulin therapy halts progression of neurodegeneration: progress in Alzheimer's disease therapeutics.

Authors:  Suzanne M de la Monte
Journal:  Aging health       Date:  2012

3.  The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease.

Authors:  Caitriona M Long-Smith; Sean Manning; Paula L McClean; Meghan F Coakley; Domhnall J O'Halloran; Christian Holscher; Cora O'Neill
Journal:  Neuromolecular Med       Date:  2012-09-21       Impact factor: 3.843

4.  A Pilot Study of Exenatide Actions in Alzheimer's Disease.

Authors:  Roger J Mullins; Maja Mustapic; Chee W Chia; Olga Carlson; Seema Gulyani; Joyce Tran; Yazhou Li; Mark P Mattson; Susan Resnick; Josephine M Egan; Nigel H Greig; Dimitrios Kapogiannis
Journal:  Curr Alzheimer Res       Date:  2019       Impact factor: 3.498

5.  Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury.

Authors:  Nigel H Greig; David Tweedie; Lital Rachmany; Yazhou Li; Vardit Rubovitch; Shaul Schreiber; Yung-Hsiao Chiang; Barry J Hoffer; Jonathan Miller; Debomoy K Lahiri; Kumar Sambamurti; Robert E Becker; Chaim G Pick
Journal:  Alzheimers Dement       Date:  2014-02       Impact factor: 21.566

6.  Central Nervous System Delivery of Intranasal Insulin: Mechanisms of Uptake and Effects on Cognition.

Authors:  Therese S Salameh; Kristin M Bullock; Isabel A Hujoel; Michael L Niehoff; Tami Wolden-Hanson; Junghyun Kim; John E Morley; Susan A Farr; William A Banks
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 7.  Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?

Authors:  David J Grieve; Roslyn S Cassidy; Brian D Green
Journal:  Br J Pharmacol       Date:  2009-08       Impact factor: 8.739

Review 8.  Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases.

Authors:  Valeria Calsolaro; Paul Edison
Journal:  CNS Drugs       Date:  2015-12       Impact factor: 5.749

9.  AlzPathway: a comprehensive map of signaling pathways of Alzheimer's disease.

Authors:  Satoshi Mizuno; Risa Iijima; Soichi Ogishima; Masataka Kikuchi; Yukiko Matsuoka; Samik Ghosh; Tadashi Miyamoto; Akinori Miyashita; Ryozo Kuwano; Hiroshi Tanaka
Journal:  BMC Syst Biol       Date:  2012-05-30

Review 10.  Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease.

Authors:  Suzanne M de la Monte
Journal:  Front Biosci (Elite Ed)       Date:  2012-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.